Differential activation of mitogen-activated protein kinases in ischemic and nitroglycerin-induced preconditioning

Previous studies have shown that the cardioprotective effect of ischemic preconditioning (IPC) can be mimicked pharmacologically with clinically relevant agents, including nitric oxide (NO) donors. However, whether pharmacological preconditioning shares the same molecular mechanism with IPC is not fully elucidated. The present study aimed to determine the activation of mitogen-activated protein kinases (MAPKs) (ERK1/2, p38 MAPK and p46/p54 JNKs) during ischemia and at reperfusion in nitroglycerin-induced preconditioning as compared to IPC and to correlate this with the conferred cardioprotection in anesthetized rabbits. Sixty minutes of intravenous administration of nitroglycerin was capable of inducing both early and late phase preconditioning in anesthetized rabbits, as it was expressed by the reduction of infarct size. Despite the cardioprotective effect conferred by both ischemic and nitroglycerin-induced preconditioning, there was a differential phosphorylation of MAPKs between the studied groups. p38 MAPK was activated early in ischemia in both ischemic and the early nitroglycerin-induced preconditioning while JNKs were markedly increased only after IPC. Furthermore, in these groups, ERK1/2 were activated during reperfusion. A different profile was observed in the late preconditioning induced by nitroglycerin with increased p38 MAPK and ERK1/2 phosphorylation during late ischemia. No activation of JNKs was observed at any time point in this group. It seems that activation of individual MAPK subfamilies depends on the nature of preconditioning stimulus. Returned for 1st revision: 18 November 2005 1st revision received: 3 January 2006 Returned for 2nd revision: 19 January 2006 2nd revision received: 6 February 2006 Returned for 3rd revision: 22 February 2006 3rd revision received: 1 March 2006     

C反应蛋白通过CD32影响人内皮祖细胞分泌白细胞介素8

目的研究C反应蛋白(CRP)对人外周血内皮祖细胞(EPCs)分泌白细胞介素8(IL-8)的影响。方法EPCs经培养鉴定后,分别加入浓度为0、5、10、25 mg/L的人重组CRP共同培养,依次设为对照组及低、中、高浓度组;另取EPCs分别加0、10 mg/L人重组CRP分为实验组和CRP组,先经抗CD32抗体(抗CD32组)、抗CD16抗体(抗CD16组)预处理后,再与人重组CRP 10 mg/L共同培养;以ELISA检测IL-8表达,以实时定量PCR检测CD32、CD16 mRNA的表达。结果与对照组比较,中、高浓度组显著抑制EPCs分泌IL 8(P<0.05);与实验组比较,CRP组IL-8降低;与CRP组比较,抗CD32组可拮抗CRP的作用(P<0.05),EPCs不表达CD16 rnRNA,表达CD32 mRNA。结论CRP抑制EPCs分泌IL-8,可能与CD32相关。     

Activation of mitogen-activated protein kinases in human heart during cardiopulmonary bypass

Mitogen-activated protein kinases (MAPKs) have been shown to be activated in both in vitro and in vivo models of cardiac tissue in response to ischemia/reperfusion injury. We investigated whether MAPKs are activated in human heart during coronary artery bypass grafting (CABG) surgery. During elective CABG surgery of 8 patients, 3 right atrial appendage biopsies were obtained at baseline, at the end of cross-clamping, and after coronary reperfusion. The expression of the p38-MAPK, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinases (ERK1/2) MAPKs was not altered during CABG. The phosphorylation and activation of both ERK1/2 and p38-MAPK were increased approximately 2-fold by ischemia and even more (8- and 4-fold, respectively) by reperfusion. Although the ischemic period did not result in a significant activation of JNK, an approximately 6-fold increase in JNK activity could be observed after reperfusion. In conclusion, distinct activation patterns of ERK1/2, p38, and JNK MAPKs can be observed in human heart during CABG.     

Stage-specific differential activation of mitogen-activated protein kinases in hypertrophied and failing rat hearts

Mitogen-activated protein kinases (MAPKs) are involved in the early development of cardiac hypertrophy, but their roles in chronic left ventricular hypertrophy (LVH) are unclear. We studied the angiotensin (Ang) II-induced cardiac MAPK activation of the hypertensive Dahl salt-sensitive (DS) rats in the subacute developing LVH stage, the chronic compensated LVH stage, and the congestive heart failure (CHF) stage. In the isolated, coronary-perfused heart preparation, Ang II infusion (1x10(-6)mol/l) activated extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38-MAPK in the LV myocardium. No substantial differences were observed in the Ang II-induced ERK activation between the normotensive control DS rats and the hypertensive DS rats in either stage. In contrast, the Ang II-induced activation of JNK and p38-MAPK was augmented in the subacute LVH stage of the hypertensive DS rats, but then progressively attenuated in the chronic LVH and CHF stages. Chronic treatment with an angiotensin converting enzyme inhibitor, temocapril (20 mg/kg/day), ameliorated the responsiveness of the JNK/p38-MAPK activation, suggesting that the decreased JNK/p38-MAPK activation is a consequence of negative feedback regulation for the activated cardiac renin-angiotensin system in chronic LVH and CHF. Thus, the Ang II-induced activation of multiple cardiac MAPK pathways are differentially regulated, depending on the stages of chronic hypertrophic process. The JNK and p38-MAPK activation may be involved in the early development of adaptive LVH. However, the responsiveness of the cardiac JNK/p38-MAPK pathways progressively decreased in chronic LVH and CHF under the chronic activation of tissue renin-angiotensin system.     

Reciprocal modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatase 1 and 2 in failing human myocardium

BACKGROUND: Mitogen-activated protein kinases (MAPKs), consisting of the ERK1/2, JNKs, and p38-kinase families, play a key role in the regulation of myocyte growth and apoptosis in vitro. The activity of MAPKs is regulated by dual-specificity MAPK phosphatases (MKPs). Because myocardial failure is associated with myocyte hypertrophy and apoptosis, MAPKs may play a pathophysiologic role in human myocardial failure. METHODS AND RESULTS: We measured MAPKs activities and the protein levels of MAPKs and MKPs (MKP-1 and MKP-2) in the myocardium explanted at the time of transplantation from patients with end-stage failure caused by idiopathic dilated cardiomyopathy (n = 5-7). Nonfailing donor hearts (n = 5-7) were used for comparison. Although the protein levels for JNK1/2 and p38-kinase in failing hearts were not different from levels in nonfailing hearts, the activities of both were decreased (P <.05). Despite a >3-fold increase in the protein level for ERK1/2 in failing hearts, ERK1/2 activity was not increased. Expression of MKP-2 was significantly increased in failing hearts, while expression of MKP-1 was increased in 5 of 7 failing hearts as measured by Western analysis. CONCLUSIONS: JNK1/2 and p38 activities are decreased in failing human myocardium. Increased expression of MKPs may therefore contribute to decreased MAPKs activity in failing human myocardium.     

Eotaxin induces degranulation and chemotaxis of eosinophils through the activation of ERK2 and p38 mitogen-activated protein kinases

Eotaxin and other CC chemokines acting via CC chemokine receptor-3 (CCR3) are believed to play an integral role in the development of eosinophilic inflammation in asthma and allergic inflammatory diseases. However, little is known about the intracellular events following agonist binding to CCR3 and the relationship of these events to the functional response of the cell. The objectives of this study were to investigate CCR3-mediated activation of the mitogen-activated protein (MAP) kinases extracellular signal-regulated kinase-2 (ERK2), p38, and c-jun N-terminal kinase (JNK) in eosinophils and to assess the requirement for MAP kinases in eotaxin-induced eosinophil cationic protein (ECP) release and chemotaxis. MAP kinase activation was studied in eotaxin-stimulated eosinophils (more than 97% purity) by Western blotting and immune-complex kinase assays. ECP release was measured by radioimmunoassay. Chemotaxis was assessed using Boyden microchambers. Eotaxin (10(-11) to 10(-7) mol/L) induced concentration-dependent phosphorylation of ERK2 and p38. Phosphorylation was detectable after 30 seconds, peaked at about 1 minute, and returned to baseline after 2 to 5 minutes. Phosphorylation of JNK above baseline could not be detected. The kinase activity of ERK2 and p38 paralleled phosphorylation. PD980 59, an inhibitor of the ERK2-activating enzyme MEK (MAP ERK kinase), blocked phosphorylation of ERK2 in a concentration-dependent manner. The functional relevance of ERK2 and p38 was studied using PD98 059 and the p38 inhibitor SB202 190. PD98 059 and SB202 190 both caused inhibition of eotaxin-induced ECP release and chemotaxis. We conclude that eotaxin induces a rapid concentration-dependent activation of ERK2 and p38 in eosinophils and that the activation of these MAP kinases is required for eotaxin-stimulated degranulation and directed locomotion. (Blood. 2000;95:1911-1917)     

Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells

Angiostatin is an endogenous inhibitor of angiogenesis that was isolated from tumor-bearing mice. It has been established that angiostatin inhibits endothelial cell proliferation; however, the underlying mechanisms remain to be elucidated. Here we report that angiostatin reduces transiently the phosphorylation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular cells, but not in human vascular smooth muscle cells or human dermal fibroblasts. We demonstrate that angiostatin diminishes ERK activation by basic fibroblast growth factor and vascular endothelial growth factor. Dephosphorylation of ERK and other tyrosine-phosphorylated proteins was blocked by pretreatment of the cells with sodium meta-vanadate, an inhibitor of protein tyrosine phosphatases, indicating that angiostatin signaling may require the activity of a tyrosine phosphatase. Concentrations of angiostatin that inhibited ERK activation also inhibited basic fibroblast growth factor-stimulated collagen gel invasion by endothelial cells, but did not affect endothelial cell proliferation. We thus show that angiostatin inhibits primarily the invasion of endothelial cells and exerts minimal (if any) effects on their proliferation. Invasion is a process that involves proteolysis, adhesion and migration, all of which have been linked to ERK signaling.     

实验性结肠炎p38丝裂原活化蛋白激酶表达的研究

目的观察三硝基苯磺酸（TNBS）诱导的大鼠结肠炎结肠组织p38MAPK表达与激活及大鼠血清TNF-α、IL-10水平变化,探讨p38MAPK在实验性结肠炎中的作用与机制。方法20只SD大鼠随机分为正常对照组（N）与模型组（M）,TNBS／乙醇法构建结肠炎模型,观察炎症活动指数（DAI）、大体形态损伤指数（CMDI）、组织学损伤指数（TDI）,ELISA法检测血清TNF-α、IL-10水平,免疫组化染色检测大鼠结肠p38MAPK、p-p38MAPK表达。结果与N组相比,M组DAI、CMDI、TDI显著升高（P〈0．01）,血清TNF-α升高,IL-10水平下降（P〈0．01）,结肠组织p38MAPK表达增加（P〈0．05）,p-p38MAPK表达显著增加（P〈0．01）。结论p38MAPK在实验性结肠炎的表达与激活均有明显增加,可能通过调节TNF-α、IL-10等细胞因子的表达参与结肠炎的发病。     

Infrequent activation of mitogen-activated protein kinase in human colon cancers

BACKGROUND/AIMS: Mitogen-activated protein kinase (MAPK) is a downstream factor of the Ras-Raf-MAPK cascade and it is now considered to be a key molecule in signaling processes stimulated by growth factors and differentiation inducers. METHODOLOGY: We examined MAPK activity in 21 advanced colon cancers to investigate whether the MAPK cascade might play a role in the progression of colon cancers. RESULTS: MAPK activation (3.9-10.1-fold) was observed in 4 of 21 cases (18%), but 3 cases (75%, 3 of 4 cases) showed MAPK activation without ras mutation, thus suggesting that MAPK activation did not correlate with the presence of Ki-ras mutations in these cases. Other kinds of oncogene activation would be involved to MAPK activation in human colon cancers. In other cases MAPK activation was not detected or partly down-regulated. CONCLUSIONS: These findings suggest that positive and negative regulation of MAPK activity are associated with loss of normal growth control and may be involved in carcinogenesis of colon cancers.     

Cytochrome P4502E1 sensitizes to tumor necrosis factor alpha-induced liver injury through activation of mitogen-activated protein kinases in mice

The goal of this study was to evaluate the role of mitogen-activated protein kinase (MAPK) in cytochrome P4502E1 (CYP2E1) potentiation of lipopolysaccharide or tumor necrosis factor alpha (TNF-alpha)-induced liver injury. Treatment of C57/BL/6 mice with pyrazole (PY) plus lipopolysaccharide (LPS) induced liver injury compared with mice treated with PY or LPS alone. The c-Jun N-terminal kinase (JNK) inhibitor SP600125 or p38 MAPK inhibitor SB203580 prevented this liver injury. PY plus LPS treatment activated p38 MAPK and JNK but not extracellular signal-regulated kinase (ERK). PY plus LPS treatment triggered oxidative stress in the liver with increases in lipid peroxidation, decrease of glutathione (GSH) levels, and increased production of 3-nitrotyrosine adducts and protein carbonyl formation. This oxidative stress was blocked by SP600125 or SB203580. PY plus LPS treatment elevated TNF-alpha production, and this was blocked by SP600125 or SB203580. Neither SP600125 nor SB203580 affected CYP2E1 activity or protein levels. Treating C57/BL/6 mice with PY plus TNF-alpha also induced liver injury and increased lipid peroxidation and decreased GSH levels. Prolonged activation of JNK and p38 MAPK was observed. All of these effects were blocked by SP600125 or SB203580. In contrast to wild-type SV 129 mice, treating CYP2E1 knockout mice with PY plus TNF-alpha did not induce liver injury, thus validating the role of CYP21E1 in this potentiated liver injury. Liver mitochondria from PY plus LPS or PY plus TNF-alpha treated mice underwent calcium-dependent, cyclosporine A-sensitive swelling, which was prevented by SB203580 or SP600125. CONCLUSION: These results show that CYP2E1 sensitizes liver hepatocytes to LPS or TNF-alpha and that the CYP2E1-enhanced LPS or TNF-alpha injury, oxidant stress, and mitochondrial injury is JNK or p38 MAPK dependent.     

Ethanol enhances growth factor activation of mitogen-activated protein kinases by a protein kinase C-dependent mechanism.

Excessive alcohol consumption alters neuronal growth and causes striking elongation of axons and dendrites in several brain regions. This could result from increased sensitivity to neurotrophic factors, since ethanol markedly enhances nerve growth factor (NGF)- and basic fibroblast growth factor (bFGF)-stimulated neurite outgrowth in the neural cell line PC12. The mechanism by which ethanol enhances growth factor responses was investigated by examining activation of mitogen-activated protein kinases (MAP kinases), a key event in growth factor signaling. Ethanol (100 mM) increased NGF- and bFGF-induced activation of MAP kinases. This increase, like ethanol-induced increases in neurite outgrowth, was prevented by down regulation of beta, delta, and epsilon protein kinase C (PKC) isozymes. Since chronic ethanol exposure specifically upregulates delta and epsilon PKC, these findings suggest that ethanol promotes neurite growth by enhancing growth factor signal transduction through a delta or epsilon PKC-regulated pathway.     

同型半胱氨酸对人THP-1巨噬细胞白细胞介素-8蛋白表达的影响

目的:探讨同型半胱氨酸(Hcy)对人THP-1巨噬细胞白细胞介素(IL)-8蛋白表达及分泌的影响。方法:在由0.1μmol/L佛波脂(PMA)诱导分化的人THP-1巨噬细胞中加入不同浓度的Hcy,并孵育不同时间。用酶联免疫吸附法检测培养上清液中IL-8蛋白的含量。结果:经PMA诱导后,THP-1细胞贴壁生长,分化成巨噬细胞。在一定浓度范围之内,Hcy呈剂量依赖性刺激THP-1巨噬细胞分泌IL-8蛋白,0.05mmol/L即可促进其分泌,增加为阴性对照组的1.28倍(P<0.01);0.2mmol/LHcy使IL-8的产量增加到阴性对照组的1.55倍(P<0.01)。0.1mmol/LHcy干预后,IL-8蛋白在3h即高于阴性对照组,到48h仍明显高于阴性对照组。Hcy刺激IL-8分泌呈剂量和时间依赖关系。结论:Hcy能促进人THP-1巨噬细胞IL-8的表达和分泌,可能为其诱导动脉粥样硬化的重要机制之一。     

Cigarette smoking decreases interleukin-8 secretion by human alveolar macrophages

Cigarette smoking can impair pulmonary immune function, and hence influences the development of lung diseases. Interleukin-8 (IL-8) is a proinflammatory peptide and a potent chemotactic factor for neutrophils, and is produced by both immune and non-immune cells including monocytes and alveolar macrophages (AM). We investigated the effect of cigarette smoking on the secretion of IL-8 by human AM. The IL-8 concentration in bronchoalveolar lavage fluid (BALF) was much higher in smokers than in non-smokers (18.4 +/- 3.9 vs 4.1 +/- 1.0 pg ml-1; P < 0.005). However, spontaneous IL-8 secretion by cultured AM was lower in smokers than in non-smokers (46.8 +/- 12.7 vs 124.1 +/- 24.0 ng ml-1; P < 0.01). When stimulated with lipopolysaccharide (LPS), AM from smokers secreted significantly less IL-8 than those from non-smokers at all tested concentrations of LPS. In contrast, the amount of IL-8 secreted by peripheral blood monocytes with or without LPS stimulation was comparable in smokers and non-smokers. These observations indicate that smoking decreases IL-8 secretion by AM, which may modify or decrease the inflammatory response in the lung.